EXCIPIENT UPDATE – Addressing Challenges With Low-Solubility Compounds: The Importance of Functional Excipients in the Formulation of Amorphous Dispersions
Rod Ray, PhD, explains that because more than half of the compounds in early development are considered poorly soluble, improving oral bioavailability represents a significant challenge to the pharmaceutical industry.
N.V. Satheesh Madhav, PhD, MPharm; and Pranshu Tangri, MPharm; formulate and evaluate sustained-release tablets of atorvastatin using a biomaterial isolated from unripe fruit pulp as a novel biobinder for the formulation of tablets.
Dr. Colin Minchom, VP of Hovione’s Particle Design business unit, discusses how the company is evolving and adapting in the current market and reviews its new Particle Design offering.
Johannes BartholomÃ¤us, PhD; Judy Ashworth, MD; Hans-Jürgen Stahlberg, MD; Eric Galia, PhD; and Kai Strothmann, PhD; examine an innovative drug delivery platform that can significantly raise the hurdle for misuse or abuse of tablets by routes of administration that require the product to first be crushed.
LYOPHILIZATION – Making Formulations More Efficient Using the Freeze-Dry Microscopy Pre-Lyophilization Method
Jeffrey McGinn says to minimize cost and streamline this process, many companies developing new parenterals are finding it in their best interest to optimize their lyophilization cycles by looking at pre-lyophilization methods such as freeze-dry microscopy.
Dinesh Haswani, PhD; John Nagel, MBA; Derek Moe, PhD; and Ehab Hamed, PhD; say formulations developed using OraGuard technology provide overlapping resistance against various tampering methods, such as crushing and ingestion, chewing, small-volume extract
BIOAVAILABILITY ENHANCEMENT – Overcoming Poorly Soluble Pharmaceutical Formulations With Hot Melt Extrusion
INTRODUCTION Solubility is an essential characteristic of active pharmaceutical ingredients (APIs), with profound effects on process and clinical development, formulation, and commercialization. Higher-solubility drugs dissolve…
FORMULATION DEVELOPMENT – Recombinant Human Albumin: Delivering the Future of Type 2 Diabetes Medication
Mark Perkins, PhD, discusses the application of human serum albumin as a half-life extension technology for GLP-1 therapeutics and how further developments in recombinant human albumin technology may further change the dosing paradigm.
EXECUTIVE INTERVIEW – DPT Laboratories: Providing Solutions to Sterile & Non-Sterile Development & Manufacturing of Semi-Solid & Liquid Dosage Forms
Paul Johnson, DPT Group President & Chief Operating Officer, talks about the consistent growth and success of DPT, its expansion in the sterile arena, and plans for the future.
DRUG DELIVERY – Hyaluronic Acid: An Ideal Ingredient for Slow-Release Formulations for Osteoarthritis Treatment
Morten J. Maltesen, PhD; and Ole M. Dall, MSc; believe that in addition to its physiological and biological effects in the joints, HA exhibits significant structural and rheological properties that make it an attractive carrier for drug delivery applications.
EXCLUSIVE ONLINE CONTENT
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
Accenture recently announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its……
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes……
AC Immune SA recently announced it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of….
DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….